JPMorgan Chase & Co. acquired 46,951 shares of TIGERMED (H shares) by taking a security interest via an off-exchange transaction at an average of HKD 39.5698 per share on November 4, 2026, involving about HKD 1.86 million; the transaction was settled in cash, was not matched on the SEHK open market, and therefore was not a direct secondary-market dealing.
Prior to the acquisition, JPMorgan Chase & Co.’s long position in TIGERMED was 23.39 million shares, representing 18.99%; following the acquisition, the holding changed to 23.43 million shares, with the long position ratio rising to 19.03%.
Source: Hong Kong Exchanges and Clearing Limited.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments